

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY MEMBER STATE OF THE EEA (OTHER THAN ANY MEMBER STATE OF THE EEA WHERE THE COMPANY'S SECURITIES MAY BE LEGALLY MARKETING), OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER TO ISSUE OR SELL, OR ANY SOLICITATION OF ANY OFFER TO SUBSCRIBE OR PURCHASE, ANY INVESTMENTS IN ANY JURISDICTION.

#### BARONSMEAD VENTURE TRUST PLC

LEI: 213800VQ1PQHOUXDDQ88

20 November 2025

#### Allotment of Shares and Total Voting Rights

The Board of Baronsmead Venture Trust plc (the "**Company**") announced on 13 October 2025 that the Company, together with Baronsmead Second Venture Trust plc, had published a prospectus (the "**Prospectus**") in relation to offers for subscription to raise up to £30 million in aggregate with the discretion to utilise over-allotment facilities to raise up to a further £20 million in aggregate (the "**Offers**" and each an "**Offer**").

On 20 November 2025 and in accordance with the Allotment Formula set out in the Prospectus, the Company allotted 9,262,181 Ordinary Shares of 10 pence each (the "**New Ordinary Shares**") in the capital of the Company pursuant to the first allotment under the Offer conditional only on Admission (the timetable for which is set out in more detail below). The New Ordinary Shares were issued at prices of between 52.79 pence per New Ordinary Share and 55.48 pence per New Ordinary Share, depending on the amount of Offer Costs, any Initial Commission waived, any Initial Adviser Charges, any Early Subscription Incentive associated with an Application and based on the net asset value per Ordinary Share as at 31 October 2025 (as announced on 6 November 2025, being the last published net asset value per Ordinary Share). The average issue price was 53.51 pence per share.

Application will shortly be made for the New Ordinary Shares to be admitted to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange plc's main market for listed securities ("**Admission**"). It is expected that Admission will occur and dealing will commence in the New Ordinary Shares on or around 27 November 2025. When issued, the New Ordinary Shares will rank pari passu with the existing Ordinary Shares.

As a result of the issue, the total number of Ordinary Shares in issue will be 480,569,282 (including the 53,541,671 Ordinary Shares currently held in Treasury with each Ordinary Share carrying one vote each). Therefore, the total voting rights in the Company will be 427,027,611. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.

The New Ordinary Shares will be issued in registered form and may be held in uncertificated form. Definitive documents of title are expected to be dispatched within 10 business days of allotment. The New Ordinary Shares will be eligible for settlement through CREST with effect from Admission.

Unless the context requires otherwise, terms defined in the Prospectus have the same meaning where used in this announcement.

#### For further information please contact:

Baronsmead VCT Investor Relations  
020 7382 0999  
[baronsmeadvcts@greshamhouse.com](mailto:baronsmeadvcts@greshamhouse.com)

#### Notes

This Announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the UK Financial Conduct Authority ("FCA") and is not a prospectus. This Announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares in Baronsmead Venture Trust plc or Baronsmead Second Venture Trust plc (together the "Companies") in any jurisdiction including in or into Australia, Canada, Japan, the Republic of South Africa, the

the Companies / in any jurisdiction, including in or from Australia, Canada, Japan, the Republic of Korea / Israel, the United States or any member state of the EEA (other than any member state of the EEA where the Companies' securities may be lawfully marketed). Investors should not subscribe for or purchase any ordinary shares referred to in this Announcement except on the basis of information in the prospectus (the "Prospectus") in its final form, published on 13 October 2025 by Baronsmead Venture Trust plc and Baronsmead Second Venture Trust plc, in connection with the Offer. A copy of the Prospectus is available for inspection, subject to certain access restrictions, from the Company's registered office, for viewing at the National Storage Mechanism at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism> and on the Company's website (<http://www.baronsmeadvts.co.uk>). Approval of the Prospectus by the FCA should not be understood as an endorsement of the securities that are the subject of the Prospectus. Potential investors are recommended to read the Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with a decision to invest in the Companies' securities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEURVARVUUAUAA